Partners
Introduction
Accelerate@Babraham is supported by a core group of strategic partners and supporters. Their support enables us to deliver this ground-breaking programme year after year and their expertise, knowledge and connections open doors for our start-ups that would not ordinarily be possible.
Medicines Discovery Catapult (MDC)
Medicines Discovery Catapult is an independent, not-for-profit organisation that is reshaping drug discovery for patient benefit. MDC supports the drug discovery industry, SMEs, and innovators in transforming great UK science into better treatments through partnerships.
“Medicines Discovery Catapult are excited to support Accelerate@Babraham. The programme is an amazing opportunity for early-stage innovators to gain invaluable commercial and scientific insights to accelerate their innovations. Medicines Discovery Catapult is passionate about supporting life science innovation across the UK and look forward to working with innovators on the programme to identify opportunities, optimise their resources and de-risk their programmes.”
Dr Sally-Ann Emmas, Lead Scientist, Medicines Discovery Catapult
LifeArc
LifeArc is a self-funded medical research charity, whose mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients.
“LifeArc is committed to nurturing new life science ventures in the Cambridge cluster and the wider UK life science sector. Our support of the ‘Accelerate@Babraham’ initiative enables more scientists to develop their ideas and research solutions that could potentially benefit patients.”
Enrique Millan, Investment Principal, LifeArc
AstraZeneca
A global, science-led pharmaceutical company, focused on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of unmet medical need in three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism (CVRM); and Respiratory and Immunology.
“Accelerate@Babraham is a great way not only to build relationships across the Cambridge ecosystem, but also to get early, informal feedback from big pharma in a supportive environment. If in doubt, apply!”
Laura Ferguson, Associate Director
Eisai
A leading global research & development-based pharmaceutical company headquartered in Japan. Eisai delivers innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.
“Eisai is delighted to support Accelerate@Babraham, and in doing so help to nurture the next generation of medicinal innovators. We believe that through supporting the vibrant UK innovation ecosystem, such as is being fostered by the Accelerate@Babraham initiative, we can accelerate the delivery of next-generation medicines to patients with unmet needs. A philosophy which we further support through our venture investment business. Eisai supports Accelerate@Babraham from our Hatfield Research Laboratories and this association complements our existing External Innovation collaborative working model."
Kazumasa Nagayama, Vice President Chief Strategy Officer, Eisai
Kidney Research UK
Kidney Research UK is the largest charity in the UK which funds research focused on the prevention, treatment and management of kidney disease. The vision of the charity is to free lives from the restrictions, fear, anxiety and life limiting nature of kidney disease.
“We are delighted to support Accelerate@Babraham and look forward to working with the Campus team, our fellow strategic partners and other supporters of the initiative. The partnership will enable us to forge strong connections and accelerate research into kidney disease, so it makes a difference to kidney patients’ lives faster. At this uncertain time, being ambitious and collaborating with others is crucial to ensure kidney research continues to grow.”
Marc Stowell, Director of Communications & Income Generation at Kidney Research UK
Triple Chasm
A data-led company focused on the provision of tools, programmes and bespoke services to support the successful commercialisation of disruptive innovation.
“We are delignated to be working with the Babraham team and fellow strategic partners to help the selected early-stage innovators successfully commercialise their innovative new ideas for the benefit of patients and wider society.”
Uday Phadke, CEO, Triple Chasm Company
Supporters
Accelerate@Babraham enjoys a high level of support from organisations on Campus, within the Cambridge life science cluster and beyond. These organisations offer their time, experience and expertise to our start-up ventures and we are extremely grateful for their continued support.
